$OM
Outset Medical, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024093071 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $28.67M $27.39M
YoY Change -5.59% -24.01%
Cost Of Revenue $18.85M $17.61M
YoY Change -18.78% -37.87%
Gross Profit $9.820M $9.782M
YoY Change 37.21% 26.99%
Gross Profit Margin 34.26% 35.72%
Selling, General & Admin $25.52M $30.81M
YoY Change -30.15% -15.06%
% of Gross Profit 259.88% 314.99%
Research & Development $8.139M $9.734M
YoY Change -49.37% -34.7%
% of Gross Profit 82.88% 99.51%
Depreciation & Amortization $1.391M $1.471M
YoY Change -4.73% -2.84%
% of Gross Profit 14.16% 15.04%
Operating Expenses $33.66M $40.55M
YoY Change -36.02% -20.78%
Operating Profit -$23.84M -$30.76M
YoY Change -47.55% -29.24%
Interest Expense $6.068M $6.010M
YoY Change 88.86% 93.68%
% of Operating Profit
Other Income/Expense, Net $2.149M $2.471M
YoY Change -16.48% -7.38%
Pretax Income -$27.76M -$34.30M
YoY Change -39.78% -21.88%
Income Tax $182.0K $151.0K
% Of Pretax Income
Net Earnings -$27.94M -$34.45M
YoY Change -39.5% -21.78%
Net Earnings / Revenue -97.47% -125.8%
Basic Earnings Per Share -$0.55 -$0.66
Diluted Earnings Per Share -$0.55 -$0.66
COMMON SHARES
Basic Shares Outstanding 52.09M 51.72M
Diluted Shares Outstanding 50.50K 51.88K

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.95M $168.0M
YoY Change -72.12% -4.12%
Cash & Equivalents $33.29M $37.86M
Short-Term Investments $2.659M $130.1M
Other Short-Term Assets $3.945M $4.569M
YoY Change -34.25% -12.4%
Inventory $61.44M $61.60M
Prepaid Expenses
Receivables $34.26M $34.12M
Other Receivables $0.00 $0.00
Total Short-Term Assets $275.3M $295.1M
YoY Change -3.0% -4.61%
LONG-TERM ASSETS
Property, Plant & Equipment $9.492M $10.87M
YoY Change -31.09% -25.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $484.0K $520.0K
YoY Change -49.64% -53.9%
Total Long-Term Assets $17.62M $19.40M
YoY Change -25.91% -22.53%
TOTAL ASSETS
Total Short-Term Assets $275.3M $295.1M
Total Long-Term Assets $17.62M $19.40M
Total Assets $292.9M $314.5M
YoY Change -4.77% -5.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.295M $5.255M
YoY Change 49.13% 137.03%
Accrued Expenses $22.57M $21.77M
YoY Change -34.95% -29.42%
Deferred Revenue $12.77M $13.11M
YoY Change 17.9% 20.77%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $42.43M $43.43M
YoY Change -19.98% -11.04%
LONG-TERM LIABILITIES
Long-Term Debt $197.2M $197.0M
YoY Change 103.73% 103.87%
Other Long-Term Liabilities $5.456M $5.508M
YoY Change -4.28% -6.34%
Total Long-Term Liabilities $197.2M $197.0M
YoY Change 103.73% 103.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.43M $43.43M
Total Long-Term Liabilities $197.2M $197.0M
Total Liabilities $245.1M $245.9M
YoY Change 57.61% 62.51%
SHAREHOLDERS EQUITY
Retained Earnings -$1.100B -$1.000B
YoY Change 19.16% 14.03%
Common Stock $1.112B $1.105B
YoY Change 3.36% 4.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $47.82M $68.60M
YoY Change
Total Liabilities & Shareholders Equity $292.9M $314.5M
YoY Change -4.77% -5.95%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$27.94M -$34.45M
YoY Change -39.5% -21.78%
Depreciation, Depletion And Amortization $1.391M $1.471M
YoY Change -4.73% -2.84%
Cash From Operating Activities -$20.57M -$33.34M
YoY Change -39.51% 18.31%
INVESTING ACTIVITIES
Capital Expenditures $395.0K $120.0K
YoY Change -49.36% -84.91%
Acquisitions
YoY Change
Other Investing Activities $16.27M $39.06M
YoY Change -46.81% 39.76%
Cash From Investing Activities $15.88M $38.94M
YoY Change -46.73% 43.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 121.0K 77.00K
YoY Change -97.05% -92.62%
NET CHANGE
Cash From Operating Activities -20.57M -33.34M
Cash From Investing Activities 15.88M 38.94M
Cash From Financing Activities 121.0K 77.00K
Net Change In Cash -4.572M 5.683M
YoY Change 4472.0% 28315.0%
FREE CASH FLOW
Cash From Operating Activities -$20.57M -$33.34M
Capital Expenditures $395.0K $120.0K
Free Cash Flow -$20.96M -$33.46M
YoY Change -39.73% 15.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001484612
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39513
dei Entity Registrant Name
EntityRegistrantName
Outset Medical, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0514392
dei Entity Address Address Line1
EntityAddressAddressLine1
3052 Orchard Dr.
dei Entity Address City Or Town
EntityAddressCityOrTown
San Jose
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95134
dei City Area Code
CityAreaCode
669
dei Local Phone Number
LocalPhoneNumber
231-8200
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
OM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52089795
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37859000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68509000
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
156989000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
134815000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34121000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32980000
CY2024Q2 us-gaap Inventory Net
InventoryNet
61599000
CY2023Q4 us-gaap Inventory Net
InventoryNet
49215000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4569000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5700000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
295137000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
291219000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3329000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3329000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10873000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13273000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4675000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5375000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
520000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
605000
CY2024Q2 us-gaap Assets
Assets
314534000
CY2023Q4 us-gaap Assets
Assets
313801000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5255000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5827000
CY2024Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
11431000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
19005000
CY2024Q2 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9747000
CY2023Q4 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
13459000
CY2024Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
2199000
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
3712000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
13108000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11727000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1693000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1593000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
43433000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
55323000
CY2024Q2 om Accrued Interest Noncurrent
AccruedInterestNoncurrent
1762000
CY2023Q4 om Accrued Interest Noncurrent
AccruedInterestNoncurrent
896000
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
130000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
101000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3616000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4482000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
196994000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
130113000
CY2024Q2 us-gaap Liabilities
Liabilities
245935000
CY2023Q4 us-gaap Liabilities
Liabilities
190915000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52084000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52084000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50317000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50317000
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
52000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
50000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1104994000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1084515000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-302000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
68000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1036145000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-961747000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
68599000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
122886000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
314534000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
313801000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27388000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36040000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55556000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
69507000
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
17606000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
28337000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
37559000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
55376000
CY2024Q2 us-gaap Gross Profit
GrossProfit
9782000
CY2023Q2 us-gaap Gross Profit
GrossProfit
7703000
us-gaap Gross Profit
GrossProfit
17997000
us-gaap Gross Profit
GrossProfit
14131000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9734000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14906000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22369000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28699000
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
18128000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
24985000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
39176000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
49318000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12684000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11290000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24128000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23077000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
40546000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
51181000
us-gaap Operating Expenses
OperatingExpenses
85673000
us-gaap Operating Expenses
OperatingExpenses
101094000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-30764000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-43478000
us-gaap Operating Income Loss
OperatingIncomeLoss
-67676000
us-gaap Operating Income Loss
OperatingIncomeLoss
-86963000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2471000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2668000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5569000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5316000
CY2024Q2 us-gaap Interest Expense
InterestExpense
6010000
CY2023Q2 us-gaap Interest Expense
InterestExpense
3103000
us-gaap Interest Expense
InterestExpense
11978000
us-gaap Interest Expense
InterestExpense
6045000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34303000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43913000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-74085000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-87692000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
151000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
133000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
313000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
325000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-34454000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-44046000
us-gaap Net Income Loss
NetIncomeLoss
-74398000
us-gaap Net Income Loss
NetIncomeLoss
-88017000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.9
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.9
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.79
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51880
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51880
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48951
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48951
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51391
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51391
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49085
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49085
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-34454000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-44046000
us-gaap Net Income Loss
NetIncomeLoss
-74398000
us-gaap Net Income Loss
NetIncomeLoss
-88017000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-44000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-280000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-370000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
171000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34498000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44326000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-74768000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-87846000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
122886000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2080000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
295000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8203000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-326000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-39944000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
93200000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
77000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9820000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-44000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-34454000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
68599000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
245990000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4594000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
684000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8538000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
451000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-43971000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
216286000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1043000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10105000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-280000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-44046000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
183108000
us-gaap Net Income Loss
NetIncomeLoss
-74398000
us-gaap Net Income Loss
NetIncomeLoss
-88017000
us-gaap Share Based Compensation
ShareBasedCompensation
18023000
us-gaap Share Based Compensation
ShareBasedCompensation
18643000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2931000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2898000
om Non Cash Lease Expense
NonCashLeaseExpense
700000
om Non Cash Lease Expense
NonCashLeaseExpense
603000
om Non Cash Interest Expense
NonCashInterestExpense
1241000
om Non Cash Interest Expense
NonCashInterestExpense
914000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2928000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3353000
om Provision For Inventories
ProvisionForInventories
706000
om Provision For Inventories
ProvisionForInventories
868000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-23000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-93000
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
1813000
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
87000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2953000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8919000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
13214000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-6114000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1196000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1196000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-544000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1682000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-7279000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4058000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3695000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3720000
om Increase Decrease In Accrued Warranty Liability
IncreaseDecreaseInAccruedWarrantyLiability
-1513000
om Increase Decrease In Accrued Warranty Liability
IncreaseDecreaseInAccruedWarrantyLiability
547000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1410000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2130000
om Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-766000
om Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-640000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-79247000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-72932000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
474000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1605000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
128445000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
97849000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
108829000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
129250000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20090000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29796000
om Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases
ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases
2163000
om Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases
ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases
6320000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
66524000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
68687000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6320000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30650000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36816000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71838000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76533000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41188000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39717000
us-gaap Income Taxes Paid
IncomeTaxesPaid
356000
us-gaap Income Taxes Paid
IncomeTaxesPaid
311000
us-gaap Interest Paid Net
InterestPaidNet
10102000
us-gaap Interest Paid Net
InterestPaidNet
5131000
om Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
766000
om Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
640000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
115000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
216000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
528000
om Transfer Of Inventories To Property And Equipment
TransferOfInventoriesToPropertyAndEquipment
148000
om Transfer Of Inventories To Property And Equipment
TransferOfInventoriesToPropertyAndEquipment
0
us-gaap Net Income Loss
NetIncomeLoss
-74400000
us-gaap Net Income Loss
NetIncomeLoss
-88000000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1000000000
CY2024Q2 om Cash Cash Equivalents Restricted Cash And Short Term Investments
CashCashEquivalentsRestrictedCashAndShortTermInvestments
198200000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27388000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36040000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55556000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
69507000
CY2024Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
13200000
CY2024Q2 om Revenue Performance Obligation1
RevenuePerformanceObligation1
13100000
CY2024Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2024Q2 om Revenue Performance Obligation1
RevenuePerformanceObligation1
100000
CY2024Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3300000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
8800000
om Debt Securities Available For Sale Remaining Contractual Maturities Period
DebtSecuritiesAvailableForSaleRemainingContractualMaturitiesPeriod
one month to sixteen months
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
130134000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
312000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
64877000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
74000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
3300000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
3300000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37859000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36388000
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
3329000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
3329000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41188000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39717000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
203000
us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
1820000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
7000
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2016000
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
23340000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
18706000
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
11864000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
8728000
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
26395000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
21781000
CY2024Q2 us-gaap Inventory Net
InventoryNet
61599000
CY2023Q4 us-gaap Inventory Net
InventoryNet
49215000
CY2024Q2 om Accrued Inventory Current
AccruedInventoryCurrent
3683000
CY2023Q4 om Accrued Inventory Current
AccruedInventoryCurrent
3395000
CY2024Q2 om Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
281000
CY2023Q4 om Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1050000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
896000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1153000
CY2024Q2 us-gaap Accrued Exchange Fee Rebate Current
AccruedExchangeFeeRebateCurrent
1588000
CY2023Q4 us-gaap Accrued Exchange Fee Rebate Current
AccruedExchangeFeeRebateCurrent
2100000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3299000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5761000
CY2024Q2 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
9747000
CY2023Q4 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
13459000
CY2024Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
200000000
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
133476000
CY2024Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3006000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3363000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
196994000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
130113000
om Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percentage Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageVestedInPeriod
0.50
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9820000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10105000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18023000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18643000
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6827000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6827000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5104000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5104000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges
854000
us-gaap Restructuring Charges
RestructuringCharges
2778000
us-gaap Payments For Restructuring
PaymentsForRestructuring
2889000
CY2024Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges
743000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-093071-index-headers.html Edgar Link pending
0000950170-24-093071-index.html Edgar Link pending
0000950170-24-093071.txt Edgar Link pending
0000950170-24-093071-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
om-20240630.htm Edgar Link pending
om-20240630.xsd Edgar Link pending
om-ex31_1.htm Edgar Link pending
om-ex31_2.htm Edgar Link pending
om-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
om-20240630_htm.xml Edgar Link completed